Gastric cancer: predicting immune therapy side effects
Part of Cancer, Digestive system clinical trials.
This trial studies whether blood tests before treatment can predict side effects from immunotherapy (PD-1/PD-L1 inhibitors) in people with gastric cancer. If you are about to start this type of treatment, your participation could help doctors manage side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with gastric cancer (confirmed by tissue or cell sample).
- Your overall health is fair (ECOG score 0-2, meaning you can do daily activities with some help if needed).
- You have not received PD-1 or PD-L1 inhibitor treatment before.
- You are expected to live at least 3 more months.
- You are willing to follow the study plan and give signed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at markers in your tumor to predict how well immunotherapy might work for you. It aims to create a model that helps doctors choose the best treatment for advanced gastric cancer.
This study looks at samples of blood and tissue from people with advanced stomach cancer that has spread to the belly lining. The goal is to find markers that predict how well a treatment combining HIPEC (heated chemotherapy in the belly) with immunotherapy (drugs that help your immune system fight cancer) works.
This trial uses advanced imaging (ultrasound and CT) plus a blood test to predict how well your stomach cancer will respond to chemotherapy given before surgery. The goal is to personalize your treatment and improve outcomes.
This trial tests whether a blood test (called immune proteomics) can predict how well chemotherapy and immunotherapy work in people with stomach cancer. If you qualify, you would receive standard chemo or chemo plus immunotherapy before surgery, and researchers will study your blood to see if it can guide future treatment.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This trial uses artificial intelligence to analyze CT scans, blood, and tumor tissue to predict how well your cancer will respond to chemotherapy and immunotherapy before surgery. It aims to personalize treatment for locally advanced stomach or gastroesophageal junction cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.